Cours Protalix Biotherapeutics Inc TEL AVIV STOCK EXCHANGE
Actions
US74365A1016
Recherche biotechnologique et médicale
CA 2024 * | 74,06 M 28,18 Md 67,45 M | CA 2025 * | 127 M 48,45 Md 116 M | Capitalisation | 84,01 M 31,96 Md 76,51 M |
---|---|---|---|---|---|
Résultat net 2024 * | 17 M 6,47 Md 15,48 M | Résultat net 2025 * | 70 M 26,63 Md 63,75 M | VE / CA 2024 * | 1,13 x |
Trésorerie nette 2024 * | - 0 0 | Trésorerie nette 2025 * | - 0 0 | VE / CA 2025 * | 0,66 x |
PER 2024 * |
5,48
x | PER 2025 * |
1,42
x | Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 90,23% |
Dernier transcript sur Protalix Biotherapeutics Inc
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 30/06/19 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 22/07/19 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 05/07/20 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 01/12/19 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 01/12/19 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 01/11/14 |
Varia. 1 janv. | Capi. | |
---|---|---|
+1,51% | 42,75 Md | |
+49,22% | 41,61 Md | |
+8,57% | 41,34 Md | |
-12,36% | 26,59 Md | |
+8,92% | 25,49 Md | |
-25,13% | 18,12 Md | |
+29,17% | 12,24 Md | |
-3,12% | 11,76 Md | |
+6,35% | 11 Md |